CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway

Abstract

CD133 is associated with in-vitro resistance to chemotherapy involving activation of the AKT pathway.

Chemoresistance of CD133 + colon cancer may be related with increased survivin expression

“…Since the discovery of AKT as a target of phosphoinositide 3-kinase almost two decades ago and the subsequent evidence indicating the increased cell survival upon the upregulation of AKT, there has been large interests to inhibit this pathway to treat cancer [23]. The activation of AKT survival pathway was shown to confer chemoresistance to CD133 þ CSCs in hepatocellular carcinoma and neuroblastoma [24,25]. The chemoresistance of CD133 þ cells was previously attributed to the high expression of specific ATP-binding cassette drug transporters such as ABCG2 and MDR1 [26,27].…”

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

“…− tumor cells (14)(15)(16). Indeed, the significance of activating Akt signaling in cancer stem cell is provoked by the known involvement of Akt signaling in normal stem cell biology and tumorigenesis (17)(18)(19) and by the dependence of cancer stem cell on Akt signaling.…”

Expression of CD133 in differentiated thyroid cancer of young patients

“…The specific functions and ligands of the prominins are still relatively unclear 13. In recent studies, CD133expression was correlated with poor prognosis as in colorectal cancer,14 non-small cell lung cancer15 and neuroblastoma 16…”